EXTON, Pa., Nov. 8, 2012 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that Vincent Milano, president and chief executive officer of ViroPharma, will present at the 2012 Jefferies Global Healthcare Conference at 11:20 AM GMT ( 6:20 AM ET) on Thursday, November 15, 2012. The conference is being held at the Waldorf Hilton in London. ViroPharma also announced that Charles Rowland, vice president and chief financial officer of ViroPharma, will present at the Piper Jaffray 24 th Annual Healthcare Conference at 2:00 PM ET on Wednesday, November 28, 2012. The conference is being held at the New York Palace Hotel. ViroPharma's presentations will be webcast live for investors through www.viropharma.com and available for a period of 14 days following the conferences. About ViroPharma Incorporated ViroPharma Incorporated is an international biopharmaceutical company committed to developing and commercializing novel solutions for physician specialists to address unmet medical needs of patients living with diseases that have few if any clinical therapeutic options. ViroPharma is developing a portfolio of therapeutics for rare and Orphan diseases including C1 esterase inhibitor deficiency, Friedreich's Ataxia, and adrenal insufficiency; and recurrent C. difficile infection (CDI). Our goal is to provide rewarding careers to employees, to create new standards of care in the way serious diseases are treated, and to build international partnerships with the patients, advocates, and health care professionals we serve. ViroPharma's commercial products address diseases including hereditary angioedema (HAE), seizures and C. difficile-associated diarrhea (CDAD); for full U.S. prescribing information on our products, please download the package inserts at http://www.viropharma.com/Products.aspx; the prescribing information for other countries can be found at www.viropharma.com. ViroPharma routinely posts information, including press releases, which may be important to investors in the investor relations and media sections of our company's web site, www.viropharma.com. The company encourages investors to consult these sections for more information on ViroPharma and our business. SOURCE ViroPharma Incorporated
Irish pharmaceuticals company Shire said on Friday it had arranged to hand its Dermagraft skin substitute to Organogenesis and take a $650 million loss on the disposal, which unwinds a major part of an acquisition it made less than three years ago.